# Non-Myeloablative Allogeneic Stem Cell Transplantation

> **NCT00525876** · NA · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 49 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** Rituximab
- **DRUG:** Alemtuzumab
- **PROCEDURE:** Allogeneic Stem Cell Infusion

## Key facts

- **NCT ID:** NCT00525876
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2011-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00525876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00525876, "Non-Myeloablative Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00525876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*